Hemoglobin variant analysis-HPLC

Hemoglobin variant analysis is a blood test that detects and identifies abnormal hemoglobin types (for example S, C, E) and thalassemia patterns. Using methods like electrophoresis, high-performance liquid chromatography (HPLC) or genetic testing, it distinguishes trait from disease, guides diagnosis, treatment and newborn screening, and informs genetic counseling and prenatal decisions.

Hb HPLC is indicated to diagnose and monitor haemoglobinopathies—sickle cell disease and alpha/beta thalassaemia—and to identify abnormal haemoglobin variants (HbS, HbC, HbE). It’s used in newborn screening, evaluation of unexplained or persistent microcytic anaemia, carrier and prenatal/preconception testing, and for monitoring therapy or transfusion effects when variant haemoglobins may affect management.

Normal HbA1c (measured by HPLC) is below 5.7% (below 39 mmol/mol). A1c of 5.7–6.4% (39–46 mmol/mol) suggests prediabetes; ≥6.5% (≥48 mmol/mol) indicates diabetes. In people with diabetes, treatment targets are individualized but often aim for around <7% (53 mmol/mol). Interpret results cautiously in pregnancy, anemia, or hemoglobin variants and consult a clinician.

HPLC (high-performance liquid chromatography) is commonly used to screen and help diagnose thalassemia and other hemoglobinopathies. It separates and quantifies hemoglobin fractions (HbA, HbA2, HbF) — e.g., elevated HbA2 suggests beta‑thalassemia trait. However, HPLC is not always definitive; results should be interpreted with CBC, iron studies and, when needed, confirmatory DNA/genetic testing.

The HPLC test for hemoglobin variant analysis uses high-performance liquid chromatography to separate and quantify hemoglobin fractions by retention time. It identifies common variants (HbA, HbA2, HbF, HbS, HbC), aids screening and diagnosis of thalassemias and sickle cell disease, and provides precise percentage values. It is automated and reproducible, though atypical or borderline results may need confirmatory tests.

A hemoglobin variant detected means a structurally or functionally different form of hemoglobin was found on blood testing. Variants arise from genetic changes and can be harmless carriers (traits) or cause health issues like sickle cell disease or unstable hemoglobins. Significance depends on the specific variant and its proportion; further tests, family history, and clinical evaluation determine diagnosis, treatment, and genetic counseling needs.